Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis.

Zicari AM, Zicari A, Nebbioso M, Mari E, Celani C, Lollobrigida V, Cesoni Marcelli A, Occasi F, Duse M.

Pediatr Allergy Immunol. 2014 Feb;25(1):57-63. doi: 10.1111/pai.12142. Epub 2013 Nov 17.

PMID:
24236762
2.

Vitamin D levels in children affected by vernal keratoconjunctivitis.

Zicari AM, Cafarotti A, Occasi F, Lollobrigida V, Nebbioso M, Pecorella I, De Castro G, Spalice A, Loffredo L, Villa MP, Duse M.

Curr Med Res Opin. 2017 Feb;33(2):269-274. doi: 10.1080/03007995.2016.1254602. Epub 2016 Nov 4.

PMID:
27786545
3.

Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis.

Pucci N, Caputo R, Mori F, De Libero C, Di Grande L, Massai C, Bernardini R, Novembre E.

Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):865-71.

PMID:
20943058
4.
5.

Pathogenesis of Vernal Keratoconjunctivitis and Associated Factors.

Nebbioso M, Zicari AM, Celani C, Lollobrigida V, Grenga R, Duse M.

Semin Ophthalmol. 2015;30(5-6):340-4. doi: 10.3109/08820538.2013.874483. Epub 2014 Feb 27.

PMID:
24571721
6.

Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.

Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, Campa L, Vierucci A.

Ann Allergy Asthma Immunol. 2002 Sep;89(3):298-303.

PMID:
12269651
7.

Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children.

Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S.

Jpn J Ophthalmol. 2008 Sep-Oct;52(5):357-62. doi: 10.1007/s10384-008-0577-z. Epub 2008 Nov 11.

PMID:
18991035
8.

The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.

Bobek D, Grčević D, Kovačić N, Lukić IK, Jelušić M.

Pediatr Rheumatol Online J. 2014 Dec 3;12:50. doi: 10.1186/1546-0096-12-50. eCollection 2014.

9.

A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.

Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P.

Asian Pac J Allergy Immunol. 2012 Sep;30(3):177-84.

10.

Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S.

Metabolism. 2009 Nov;58(11):1624-8. doi: 10.1016/j.metabol.2009.05.018. Epub 2009 Jul 15.

PMID:
19604520
11.

Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial.

De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, Kestelyn P.

Br J Ophthalmol. 2012 Mar;96(3):323-8. doi: 10.1136/bjophthalmol-2011-300415. Epub 2011 Oct 14.

PMID:
22001151
12.

[Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis].

Tomida I, Schlote T, Bräuning J, Heide PE, Zierhut M.

Ophthalmologe. 2002 Oct;99(10):761-7. German.

PMID:
12376851
13.

Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children.

Tesse R, Spadavecchia L, Fanelli P, Rizzo G, Procoli U, Brunetti L, Cardinale F, Miniello VL, Bellizzi M, Armenio L.

Pediatr Allergy Immunol. 2010 Mar;21(2 Pt 1):330-5. doi: 10.1111/j.1399-3038.2009.00948.x. Epub 2009 Oct 15.

PMID:
19840298
14.

Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05% cyclosporine a therapy.

Oray M, Toker E.

Cornea. 2013 Aug;32(8):1149-54. doi: 10.1097/ICO.0b013e31828ffdf8.

PMID:
23676782
15.

A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.

Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, Takamura E, Nakagawa Y, Nanba K, Fukushima A, Fujishima H.

J Ocul Pharmacol Ther. 2009 Aug;25(4):365-72. doi: 10.1089/jop.2008.0103.

PMID:
19441889
16.

An essential role for dendritic cells in vernal keratoconjunctivitis: analysis by laser scanning confocal microscopy.

Liu M, Gao H, Wang T, Wang S, Li S, Shi W.

Clin Exp Allergy. 2014 Mar;44(3):362-70. doi: 10.1111/cea.12264.

PMID:
24372712
17.

Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.

Vichyanond P, Kosrirukvongs P.

Curr Allergy Asthma Rep. 2013 Jun;13(3):308-14. doi: 10.1007/s11882-013-0345-0. Review.

PMID:
23625179
18.

Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis.

Pucci N, Novembre E, Lombardi E, Massai C, Bernardini R, Caputo R, Campa L, de Libero C, Vierucci A.

Pediatrics. 2005 Jan;115(1):e86-91.

PMID:
15629970
19.

Vernal keratoconjunctivitis: atopy and autoimmunity.

Zicari AM, Nebbioso M, Lollobrigida V, Bardanzellu F, Celani C, Occasi F, Cesoni Marcelli A, Duse M.

Eur Rev Med Pharmacol Sci. 2013 May;17(10):1419-23.

20.

Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study.

Pucci N, Caputo R, di Grande L, de Libero C, Mori F, Barni S, di Simone L, Calvani A, Rusconi F, Novembre E.

Pediatr Allergy Immunol. 2015 May;26(3):256-261. doi: 10.1111/pai.12360.

PMID:
25712437

Supplemental Content

Support Center